Ketamine Therapy Screening: Questions and Red Flags to Discuss
Questions about ketamine contraindications and suitability belong in a clinical assessment. Ketamine therapy screening should establish more than whether you are interested in treatment. It should clarify the diagnosis and treatment target, review previous care and medical risks, identify the exact product and route, and explain how monitoring and follow-up will work. A short advertisement or an online checklist cannot determine whether a treatment is appropriate for you.
The most useful red flags are gaps in that process: unclear product information, exaggerated approval claims, guaranteed outcomes, or pressure to commit before an assessment. Asking careful questions does not make you a difficult patient. It helps you understand the decision you are being invited to make.
Ask what treatment is actually being offered
The FDA's ketamine safety and approval explanation distinguishes racemic ketamine, approved for anesthesia, from Spravato, a specific esketamine nasal spray with depression indications. Ketamine's psychiatric use is off-label; that fact should not be hidden behind a broad statement that the medicine is FDA-approved.
Ask for the product name, route, and condition being treated. Clarify whether the service includes medication administration alone, psychotherapy, or separate preparation and follow-up. Do not assume that every service using the phrase ketamine therapy provides the same intervention.
A reasonable provider should explain the evidence relevant to that exact proposal and its limitations. An intravenous study is not automatic evidence for an oral or compounded nasal product. An approval for one diagnosis is not an approval for every symptom listed on a clinic's website.
Ketamine contraindications: distinguish product labeling from individual risks
The current Spravato prescribing information lists specific contraindications, including aneurysmal vascular disease or arteriovenous malformation, a history of intracerebral hemorrhage, and hypersensitivity to esketamine, ketamine, or product ingredients. These are product-specific medical terms that a clinician should interpret against your history.
Other concerns require individualized discussion, such as blood-pressure or cardiovascular problems, psychosis history, substance-use concerns, interacting medications, and pregnancy or breastfeeding. A risk factor is not automatically the same as a formal contraindication, and this list is not a self-screening tool.
Do not transfer Spravato's labeling into a universal eligibility rule for every ketamine service. Likewise, do not conceal information because you fear it may affect eligibility. A careful review may lead to proceeding, postponing, arranging further assessment, or recommending a different option. The appropriate outcome is an informed decision, not approval at any cost.
Watch the video: Ketamine: Benefits and Risks for Depression, PTSD & Neuroplasticity (Huberman Lab)
Ketamine therapy risks: ask about product quality and monitoring
The FDA's explanation of compounded-drug risks notes that compounded medicines are not FDA-approved and are not reviewed by the agency for safety, effectiveness, and quality before marketing. Compounding can serve specific patient needs, but it should not be presented as identical to an approved branded product.
Ask who supplies the medication, which clinician is responsible for the prescription, and how product and dosing information are documented. You should not have to infer the treatment from a package name or a general description of a wellness experience.
Also ask what monitoring occurs, who performs it, and how the service responds to a concerning reaction. For Spravato, supervised administration, at least two hours of observation, and a clinical discharge assessment are requirements. Other proposals need their own clearly explained safety process; the presence of a prescription alone does not answer every safety question.
Prepare a treatment history that is useful, not perfect
The NIMH guide to preparing for an appointment recommends organizing symptoms, concerns, and medication information. For a screening visit, add previous treatments, approximate dates, effects, and reasons they ended. Include psychotherapy and other interventions, not only prescriptions.
Explain the difference between a treatment that was difficult to tolerate and one that was used adequately but did not help enough. Missing details can be reconstructed with records or help from past clinicians. Do not guess or exaggerate treatment failures to meet a perceived requirement.
Describe the current target in everyday language. Is the main problem severe low mood, loss of interest, difficulty functioning, intrusive thoughts, or another concern? Screening should consider whether the diagnosis and proposed intervention match, rather than treating every unsatisfactory response to previous care as a reason for the same next medicine.
Ketamine clinic red flags: promises that replace an assessment
A guaranteed cure, a universal success rate, or a claim that everyone qualifies should prompt careful questions. Ask how the result was measured, which patients it describes, and what happened to people who discontinued or did not improve. A reassuring number should not replace an explanation of your individual uncertainties.
Be cautious when the conversation moves straight to a prepaid package without explaining screening, alternatives, or what would happen if treatment were unsuitable. Ask about cancellation and unused-session terms before making a financial commitment. Clear terms are part of informed planning, not proof of clinical quality by themselves.
Other warning signs include dismissing questions about adverse effects, suggesting that a stronger altered state guarantees better results, or failing to identify who is responsible between visits. One unanswered question does not prove misconduct, but important unresolved gaps are a reason to seek clarification or another clinical opinion.
A useful consultation includes alternatives
A review of depression assessment and care may lead to reassessing the diagnosis, reviewing medication, considering psychotherapy, or discussing other interventions. A clinic's ability to provide one treatment does not establish that it is the most appropriate next step for you.
Ask what established options remain reasonable and why an advanced intervention is being considered now. Your preferences, medical history, access to follow-up, and the burden of repeated appointments matter. Choosing another treatment is not evidence that your symptoms are less serious or that you have failed to advocate for yourself.
Do not stop prescribed care while comparing providers. Ask how a proposed change would be coordinated with your current clinician. If the screening identifies a need for more urgent or intensive care, address that need rather than treating an outpatient procedure as the only acceptable outcome.
Leave with a clear decision and review plan
At the end of an assessment, you should understand the proposed treatment, why it fits or does not fit, the important risks, and the next step. It is reasonable for the clinician to request records or further evaluation before deciding. A thoughtful pause is different from an unexplained refusal or an automatic sale.
If treatment proceeds, ask how symptoms and functioning will be measured, when benefit will be reviewed, and what would lead to stopping or changing the plan. Clarify transport, time commitments, costs, and the contact route for concerns.
If it does not proceed, ask which concern drove the decision and what alternatives or further assessments are appropriate. Do not hide the same information from another provider to obtain a different answer. The purpose of screening is to make care safer and more suitable, not to identify which clinic will agree most quickly.
Discussing an assessment with Sophroneo
Sophroneo Behavioral Health & TMS offers therapy and counseling and other mental health services from its Powder Springs and Marietta locations in the Atlanta area. Contact Sophroneo to discuss your symptoms and treatment history and confirm current services, products, and treatment locations. An assessment should begin with your needs rather than an assumption that a particular medication is the answer. This article does not establish personal eligibility or a specific ketamine route offered by the practice.
Frequently asked questions
Who should not take ketamine, and can an online questionnaire decide?
An online questionnaire may gather useful information, but deciding who should not take ketamine requires a clinical assessment of the exact product and individual history. Product, route, medical and psychiatric history, other medicines, and monitoring arrangements matter. Ask who reviews the information and how unresolved concerns are addressed.
Does a history of substance use automatically rule out every treatment?
Do not assume a universal rule. The clinician must assess the specific history, current risks, product, and treatment setting. Spravato labeling calls for considering abuse and misuse risk. Honest disclosure is essential; a blog cannot determine eligibility or the appropriate alternative.
What should I do if a clinic guarantees that treatment will work?
Ask for the evidence, outcome definition, and limitations behind the claim. No general study result guarantees an individual's outcome. Seek clarification or another qualified opinion when a promise replaces discussion of uncertainty, risks, alternatives, or how the plan will be reviewed.
In the United States, call or text 988 for emotional crisis support or suicidal thoughts. Call 911 for immediate danger or a life-threatening emergency. Do not delay urgent care while seeking treatment eligibility.
This article is educational and does not determine suitability, diagnose a condition, or provide individualized prescribing advice. Do not change treatment without your clinician.
Comments